GlassScriptPhysician profile
Craig Davitt
NPI 1801266523
$6,597.96
in general payments reported to CMS, 2019-2025
36 companies · $927 in 2025
The $927 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $47.12 · 2023: $472 · 2024: $5,034 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,292 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,292.39 |
| Education | $140.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,151.02 | 2024 | |
| Janssen Biotech, INC. | $1,147.67 | 2023-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $806.35 | 2024 | Enbrel, Tavneos, Otezla |
| Stryker Corporation | $791.81 | 2023-2025 | Mako, Accolade, Triathlon |
| Astrazeneca Pharmaceuticals LP | $540.30 | 2023-2024 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $241.69 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $190.70 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $184.97 | 2023-2024 | Acthar |
| Ucb, INC. | $183.30 | 2024 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $140.30 | 2024 | Orencia |
| Pfizer INC. | $131.65 | 2024 | |
| Ferring Pharmaceuticals INC. | $99.67 | 2021-2023 | Euflexxa |
| Genzyme Corporation | $96.07 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $89.01 | 2024 | Voquezna |
| Boston Scientific Corporation | $71.00 | 2022-2025 | Wavewriter Alpha Prime 16 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $63.19 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $62.32 | 2023-2024 | Iovera, Zilretta |
| Pacira Therapeutics, INC. | $60.69 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $52.20 | 2025 | |
| Aurinia Pharma U.S., INC. | $51.16 | 2024 | Lupkynis |
| Idorsia Pharmaceuticals US INC | $48.03 | 2024 | Quviviq |
| Genentech USA, INC. | $47.83 | 2024-2025 | Actemra |
| Solventum Corporation | $44.78 | 2025 | Prevena, V.A.C. Granufoam, V.A.C.Ulta |
| Nalu Medical, INC. | $39.53 | 2025 | Nalu Neurostimulation System |
| Ibsa Pharma INC. | $34.43 | 2025 | Tirosint, Flector, Licart |
| Collegium Pharmaceutical, INC. | $33.38 | 2024 | Belbuca |
| Lilly USA, LLC | $30.63 | 2024 | Taltz |
| Linkbio Corp | $25.28 | 2025 | |
| Smith+Nephew, INC. | $23.25 | 2025 | Pico 14 |
| Radius Health, INC. | $21.81 | 2024 | Tymlos |
| Heron Therapeutics, INC. | $17.11 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.07 | 2024 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.34 | 2024 | Ofev |
| Organon LLC | $15.29 | 2024 | |
| Sanofi-Aventis U.S. LLC | $14.20 | 2022 | |
| Celltrion USA INC. | $13.93 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Davitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.